Rhusflavanone

Rhusflavanone accounts for 0.35% of the content in the stamens of *Mesua ferrea*, with IC₅₀ values of 10.6 and 14.3 μg/mL against elastase and tyrosinase, respectively^[1].
In silico prediction shows that Rhusflavanone has more favorable druglikeness and ADMET properties compared with other tested biflavonoids, and lacks blood-brain barrier permeability^[3].
Rhusflavanone (2 mg/mL) has a logK⁰ of 3.36 and a predicted logP of 4.26, indicating that it possesses moderate lipophilicity^[3].
Rhusflavanone has a Gibbs free energy of -1907.6983 Hartree, a dipole moment of 7.9539 Debye, and a highest occupied molecular orbital-lowest unoccupied molecular orbital (HOMO-LUMO) energy gap of 7.388 eV, indicating that it possesses favorable spontaneous binding properties and relatively high chemical reactivity^[3].
The maximum negative electrostatic potential (MEP) at the ketone group of Rhusflavanone is -0.2724 eV, and the maximum positive electrostatic potential is +0.1870 eV, which identifies its active sites for electrophilic and nucleophilic interactions^[3].
Rhusflavanone inhibits the growth of HCT-116, MCF-7 and HeLa cells, with IC₅₀ values of 45.00 µM, 38.50 µM and 33.0 µM, respectively^[2].
Rhusflavanone binds to SARS-CoV-2 M_pro with a binding energy of -8.0 kcal/mol^[3].
Rhusflavanone exhibits inhibitory activity against influenza B virus (B/Panama/45/90) in MDCK cells in the CPE inhibition assay, with an EC₅₀ of 4.1 μg/mL, an IC₅₀ of 38 μg/mL, and an SI of 9.3^[4].
Rhusflavanone exhibits moderate inhibitory activity against measles virus in the CPE inhibition assay (EC₅₀ = 14 μg/mL, IC₅₀ = 21 μg/mL, SI = 2), and shows better activity in the Neutral Red assay (EC₅₀ = 5 μg/mL, IC₅₀ = 40 μg/mL, SI = 8)^[4].
Rhusflavanone inhibits HSV-2 (MS strain) in HFF cells in the CPE inhibition assay, with an SI > 6.4, an EC₅₀ of 15.7 μg/mL, and a CC₅₀ >100 μg/mL^[4].
Rhusflavanone shows no significant anti-parainfluenza virus type 3, anti-respiratory syncytial virus, or anti-adenovirus type 5 activity in MA-104 or A549 cells, and also exhibits no significant anti-influenza A virus (H1N1 and H3N2 strains) activity in MDCK cells^[4].
Rhusflavanone (200 μg/mL; 1 h) shows no activity against recombinant HIV-1 RT enzyme, exhibiting only a 14.1% inhibition rate at a concentration of 200 μg/mL^[5].
Rhusflavanone (0.025-250 μg/mL; 30 min (DPPH); 10 min (ABTS); 60 min (crocin bleaching)) exhibits antioxidant activity, with IC₅₀ values of 27.22 μg/mL (DPPH), 78.421 μg/mL (ABTS), and 49.311 μg/mL (crocin bleaching inhibition)^[3].
Rhusflavanone (0.5-10 μg/mL; 1-hour pretreatment prior to 24-hour LPS stimulation) dose-dependently inhibits NO production in LPS (HY-D1056A1)-stimulated RAW264.7 macrophages, with an inhibition rate of 50% at the concentration of 10 μg/mL, and also attenuates LPS-induced morphological changes^[3].
Rhusflavanone has a high prediction probability (Pa = 0.9), inhibits NOS2 expression, and also exhibits predicted free radical scavenging activity and antiviral activity^[3].
Rhusflavanone (100 μM; 4 h) inhibits the secretion of SPI-1 effector proteins SipA, SipB, SipC and SipD in Salmonella typhimurium strain UK-1 χ8956, without altering bacterial growth or FliC secretion^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.